Gene · 3909
LAMA3: laminin subunit alpha 3
12 sourcesgene-search-2026-11-11-0.2.0
Cite this record
ConductScience Library. LAMA3: laminin subunit alpha 3. Genes, record 3909. Release gene-search-2026-11-11-0.2.0, 11 Nov 2026. https://conductscience.org/library/genes/3909
On this page
Gene
Proteins1
Reviewed human proteins whose Swiss-Prot entry states the gene.
| UniProt entry | Protein | Length | Structures | Gene stated in |
|---|---|---|---|---|
| Q16787 | Laminin subunit alpha-3 | 3,333 | 0 | Ensembl, GeneID, HGNC |
Source UniProt
Patents31
Patents whose sequence listing contains this protein's exact sequence. A patent can list a sequence without claiming it.
| Publication | Published | SEQ ID NO | Protein | Source |
|---|---|---|---|---|
| EP 4650780 A2 | 2025-11-19 | 5557 | Q16787 | Espacenet |
| EP 4641201 A2 | 2025-10-29 | 5179 | Q16787 | Espacenet |
| JP 2025147176 A | 2025-10-06 | 7648 | Q16787 | Espacenet |
| JP 2025517969 A | 2025-06-12 | 5179 | Q16787 | Espacenet |
| JP 2025517970 A | 2025-06-12 | 5557 | Q16787 | Espacenet |
| JP 2025032204 A | 2025-03-11 | 30667 | Q16787 | Espacenet |
| JP 2025028160 A | 2025-02-28 | 7648 | Q16787 | Espacenet |
| KR 1020250010750 A | 2025-01-21 | 7648 | Q16787 | Espacenet |
| EP 4461818 A2 | 2024-11-13 | 30667 | Q16787 | Espacenet |
| JP 2024109657 A | 2024-08-14 | 7655 | Q16787 | Espacenet |
1 to 10 of 31
See all 31 patentsDrugs1
Drugs a ChEMBL mechanism record says act on the gene's protein, through Open Targets.
| Drug | ChEMBL ID | Mechanism | Action |
|---|---|---|---|
| OCRIPLASMIN | CHEMBL2095222 | Laminin hydrolytic enzyme | HYDROLYTIC ENZYME |
Source ChEMBL
Trials10
Trials of those drugs. A trial joins the gene only through a drug that acts on it.
| Trial | Drug | Phase | Results first posted | Source |
|---|---|---|---|---|
| NCT02747030 | OCRIPLASMIN | PHASE1 | ClinicalTrials.gov | |
| NCT02681809 | OCRIPLASMIN | PHASE2 | 2020-12-16 | ClinicalTrials.gov |
| NCT01429441 | OCRIPLASMIN | PHASE3 | 2016-01-11 | ClinicalTrials.gov |
| NCT00996684 | OCRIPLASMIN | PHASE2 | ClinicalTrials.gov | |
| NCT00798317 | OCRIPLASMIN | PHASE3 | 2013-01-30 | ClinicalTrials.gov |
| NCT00781859 | OCRIPLASMIN | PHASE3 | 2013-01-28 | ClinicalTrials.gov |
| NCT00428129 | OCRIPLASMIN | PHASE2 | ClinicalTrials.gov | |
| NCT00412451 | OCRIPLASMIN | PHASE2 | 2013-09-13 | ClinicalTrials.gov |
| NCT00123305 | OCRIPLASMIN | PHASE2 | ClinicalTrials.gov | |
| NCT00123266 | OCRIPLASMIN | PHASE2 | ClinicalTrials.gov |
NIH grants936
NIH grants whose papers are about the gene, through NIH's grant-paper links.
| Grant | Title | LAMA3 papers | Newest fiscal year |
|---|---|---|---|
| P30CA006927 | Comprehensive Cancer Center Program at Fox Chase | 4 | 2025 |
| P30EY025585 | NEI Center Core Grant for Vision Research | 4 | 2025 |
| UL1TR001863 | Yale Clinical and Translational Science Award | 4 | 2025 |
| P30CA008748 | Cancer Center Support Grant | 3 | 2025 |
| P30CA023074 | University of Arizona Cancer Center - Cancer Center Support Grant | 3 | 2025 |
| T32CA009560 | Carcinogenesis Training Program | 3 | 2025 |
| F30DE029105 | Biofunctional sealant with peptides to extend lifespans of Class V restorations | 2 | 2025 |
| P20GM130423 | The Kansas Institute for Precision Medicine | 2 | 2025 |
| P30CA013330 | Cancer Center Support Grant | 2 | 2025 |
| P30CA014089 | University of Southern California Norris Comprehensive Cancer Center Support Grant (CCSG) | 2 | 2025 |
1 to 10 of 936Source NIH's project files
See all 936 nih grantsPapers1,589
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| Trio-Based Whole-Exome Sequencing Identifies Convergent Epithelial Junction-Related Pathways in Syndromic Hidradenitis Suppurativa. | Dermatology | 2026 | 42709635 | PubTator, text mining | PubMed |
| Syndecan-2 enhances invasive motility in colon cancer cells via a laminin-332-integrin α6β1 axis. | J Biol Chem | 2026 | 42607888 | PubTator, text mining | PubMed |
| Single-Cell Transcriptome Analysis Reveals IRF1-Driven Epithelial States and Glycosaminoglycan-Glycolysis Coupling in Cisplatin-Resistant HGSOC. | Cancer Inform | 2026 | 42605287 | PubTator, text mining | PubMed |
| Stromal Laminin Subunit Alpha 3 is a Novel Prognostic Marker for Breast Cancer. | Clin Med Insights Oncol | 2026 | 42558819 | PubTator, text mining | PubMed |
| Rare Coexistence of Familial Laryngo-Onycho-Cutaneous Syndrome (LOCS/Shabbir Syndrome) and Epidermolysis Bullosa With Multisystemic Involvement: A Case Series. | Clin Case Rep | 2026 | 42548784 | PubTator, text mining | PubMed |
| Molecular plasticity of LAMA3 across the disease spectrum: pathogenic mechanisms and clinical translation. | Histochem Cell Biol | 2026 | 42507193 | PubTator, text mining | PubMed |
| 5-Fluorouracil loaded copper‑aluminum layered double hydroxides inhibit colorectal cancer cells by inducing oxidative stress, mitochondrial membrane depolarization, apoptosis, and cell cycle arrest. | Bioorg Chem | 2026 | 42456411 | PubTator, text mining | PubMed |
| Layer-by-layer assembly of bioactive nanofilms for in situ gene transfection of a LAMA3 mutant on hydrogenated TiO₂ nanotubes: in vitro evaluation of epithelial adhesion and hemidesmosome formation. | BMC Oral Health | 2026 | 42449345 | PubTator, text mining | PubMed |
| Proteomic Analysis of Extracellular Vesicles Reveals Vitronectin and Laminin Subunit Alpha-3 as Candidate Biomarkers for Gastric Cancer. | Gut Liver | 2026 | 42366969 | PubTator, text mining | PubMed |
| Engineered Caf1 constructs encoding laminin-332 motifs: a novel approach for enhanced cutaneous wound healing. | Br J Dermatol | 2026 | 42263674 | PubTator, text mining | PubMed |
1 to 10 of 1,589
See all 1,589 papersSources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this gene from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/genes/v1/3909
GET https://conductscience.org/api/genes/v1/3909/patents?page=2